Infectious Disease Research Institute (IDRI)

51 articles with Infectious Disease Research Institute (IDRI)

• Amyris and The Infectious Disease Research Institute Partner to Advance Novel RNA Vaccine Platform Beginning With COVID-19 Application

  7/27/2020

   Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets and IDRI (Infectious Disease Research Institute) today announce the signing of a binding term sheet for a planned COVID-19 RNA (ribonucleic acid) vaccine technology program. The program combines IDRI's expertise in combating i

• Infectious Disease Research Institute (IDRI) Release: Promising New Leprosy Vaccine Moves Into Human Trials

  10/12/2017

• Infectious Disease Research Institute (IDRI) To Continue Development Of Inhalable TB Drug Candidate

  8/24/2017

• Infectious Disease Research Institute (IDRI) Receives $15 Million Commitment From Eli Lilly For TB Drug Discovery

  11/3/2016

• Infectious Disease Research Institute (IDRI) Receives FDA Grant To Develop RNA-Based Zika Virus Vaccine

  10/7/2016

• Infectious Disease Research Institute (IDRI) Adds Viral Vaccine Development Expertise; Expands Leadership

  4/13/2016

• Infectious Disease Research Institute (IDRI) And Sanofi Pasteur Team With Philanthropy To Develop New Model For Vaccine Development

  10/15/2015

• Infectious Disease Research Institute (IDRI) And Wellcome Trust Team For Tuberculosis Vaccine Trial In South Africa

  9/17/2015

• Amyris, Inc. And Infectious Disease Research Institute (IDRI) Announce Agreement To Explore Testing And Development Of Amyris Materials For Use In Vaccine Adjuvant Formulations

  9/9/2015

• Infectious Disease Research Institute (IDRI) Announces $4M Biomedical Advanced Research and Development Authority (BARDA) Cooperative Agreement To Establish Adjuvant Hub

  2/19/2015

• Infectious Disease Research Institute (IDRI) Announces $11.9M Contract To Develop Thermostable TB Vaccine

  11/20/2014

• Infectious Disease Research Institute (IDRI) Announces $11.9M Contract To Develop Thermostable TB Vaccine

  11/19/2014

• Infectious Disease Research Institute (IDRI) and Zydus Sign Agreement for Development of IDRI's Vaccine Candidate for Visceral Leishmaniasis (Kala-Azar)

  7/25/2013

• Infectious Disease Research Institute (IDRI) and Medicago, Inc. Report Positive Results for Phase I Clinical Trial for an H5N1 Vaccine

  4/18/2013

• Infectious Disease Research Institute (IDRI) and Medicago, Inc. to Present Data at the World Vaccine Congress

  4/9/2013

• Infectious Disease Research Institute (IDRI) and Medicago, Inc. Announce FDA Authorization to Initiate a Phase 1 Clinical Trial for an H5N1 Vaccine With GLA Adjuvant

  8/16/2012

• Infectious Disease Research Institute (IDRI) Expands Board, Adding Additional International Expertise With Dr Massimo Radaelli

  7/3/2012

• Soligenix Announces Collaboration with Infectious Disease Research Institute (IDRI) to Develop Thermostabilized Biodefense Vaccines Utilizing Novel Adjuvants

  6/27/2012

• Infectious Disease Research Institute (IDRI) Signs Lease with Alexandria Real Estate Equities, Inc. for New Seattle Headquarters

  5/31/2012

• Aeras Global TB Vaccine Foundation and Infectious Disease Research Institute (IDRI) Sign Agreement to Jointly Develop Novel Tuberculosis Vaccine

  5/10/2012